Selected article for: "current drug development and drug development"
Author: Kinast, Volker; Burkard, Thomas L; Todt, Daniel; Steinmann, Eike
Title: Hepatitis E Virus Drug Development
  • Cord-id: 5rsk6g7l
  • Document date: 2019_5_28
    • ID: 5rsk6g7l
    Snippet: Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in immunocompromised patients. The current therapy options are limited to the unspecific antivirals Ribavirin (RBV) and pegylated Interferon-α (pegIFN-α). RBV leads to viral clearance in only 80% of patients treated, and is, similar to pegIFN-α, contraind
    Document: Hepatitis E virus (HEV) is an underestimated disease, leading to estimated 20 million infections and up to 70,000 deaths annually. Infections are mostly asymptomatic but can reach mortality rates up to 25% in pregnant women or become chronic in immunocompromised patients. The current therapy options are limited to the unspecific antivirals Ribavirin (RBV) and pegylated Interferon-α (pegIFN-α). RBV leads to viral clearance in only 80% of patients treated, and is, similar to pegIFN-α, contraindicated in the major risk group of pregnant women, emphasizing the importance of new therapy options. In this review, we focus on the urgent need and current efforts in HEV drug development. We provide an overview of the current status of HEV antiviral research. Furthermore, we discuss strategies for drug development and the limitations of the approaches with respect to HEV.

    Search related documents:
    Co phrase search for related documents
    • act antiviral and acute infection: 1
    • act antiviral and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8
    • active compound and acute infection: 1
    • active compound and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • active compound and liver cirrhosis: 1
    • activity guide and acute infection: 1, 2
    • activity guide and acute sars cov respiratory syndrome coronavirus: 1
    • acute hepatitis and additive effect: 1
    • acute hepatitis and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute hepatitis cause and additive effect: 1
    • acute hepatitis cause and liver cirrhosis: 1
    • acute illness and additive effect: 1
    • acute illness and liver cirrhosis: 1
    • acute infection and additive effect: 1, 2
    • acute infection and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute sars cov respiratory syndrome coronavirus and additive effect: 1, 2, 3, 4, 5, 6
    • acute sars cov respiratory syndrome coronavirus and liver cirrhosis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14